Rigel Pharmaceuticals, Inc.

NASDAQ:RIGL

18.93 (USD) • At close June 20, 2025
Bedrijfsnaam Rigel Pharmaceuticals, Inc.
Symbool RIGL
Munteenheid USD
Prijs 18.93
Beurswaarde 338,324,532
Dividendpercentage 0%
52-weken bereik 7.48 - 29.82
Industrie Biotechnology
Sector Healthcare
CEO Mr. Raul R. Rodriguez
Website https://www.rigel.com

An error occurred while fetching data.

Over Rigel Pharmaceuticals, Inc.

Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is in phase III

Vergelijkbare Aandelen

Athira Pharma, Inc. logo

Athira Pharma, Inc.

ATHA

0.303 USD

Fulcrum Therapeutics, Inc. logo

Fulcrum Therapeutics, Inc.

FULC

6.995 USD

BioXcel Therapeutics, Inc. logo

BioXcel Therapeutics, Inc.

BTAI

1.6 USD

Heron Therapeutics, Inc. logo

Heron Therapeutics, Inc.

HRTX

2 USD

HilleVax, Inc. logo

HilleVax, Inc.

HLVX

1.86 USD

Absci Corporation logo

Absci Corporation

ABSI

2.79 USD

ALX Oncology Holdings Inc. logo

ALX Oncology Holdings Inc.

ALXO

0.484 USD

Mind Medicine (MindMed) Inc. logo

Mind Medicine (MindMed) Inc.

MNMD

7.05 USD

C4 Therapeutics, Inc. logo

C4 Therapeutics, Inc.

CCCC

1.42 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)